Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CIPROFLOXACIN

All products: not a benefit

Other products in the same Health Canada class (S01AE) — coverage varies; not interchangeable

  • Ofloxacin (Ocuflox): limited Use 170

Sandoz Ciprofloxacin · DIN 02387131 · 0.3% · Oph Sol-5mL Pk

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-20
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sandoz Ciprofloxacin · DIN 02387131 Manufacturer: Sandoz Canada Inc.; listing date 2012-09-28 Health Canada: Marketed since 2012-07-03 · brand SANDOZ CIPROFLOXACIN · ATC S01AE03 CIPROFLOXACIN · form Solution · route Ophthalmic · ingredients CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 0.3 % · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87272 · Verify on the e-Formulary ↗ (DIN 02387131)

Source record
DIN 02387131: Sandoz Ciprofloxacin Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 520412012; group id 586; item number 1543; lccId None; manufacturer id SDZ Source form: Oph Sol-5mL Pk; strength: 0.3% Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $9.3000; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02387131 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87272
Interchangeable products
Apo-Ciproflox · DIN 02263130 · not recorded Ciloxan · DIN 01945270 · not recorded
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (52:04:12 Other Anti-Infectives) and how they are covered

Matched class: 52:04:12 Other Anti-Infectives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. No displayed product is listed as a general benefit in this extract. Check its listing requirements below. 52:04:12 Other Anti-Infectives

OFLOXACIN

· 1 products · Limited Use, codes 170 · strengths: 0.3% · Oph Sol Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 52:04:12
Full class listing Related classes: 52:04:04 Antibiotics, 52:08:92 Anti-Inflammatory Agents, Miscellaneous Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE CILOXAN® (ciprofloxacin ophthalmic solution) is indicated for the treatment of the following infections of the eye and its adnexae when caused by susceptible strains of the designated bacteria. Corneal Ulcers: Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae. Conjunctivitis: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus (Viridans group), Streptococcus pneumoniae, Haemophilus influenzae. CILOXAN® (ciprofloxacin ophthalmic ointment) is indicated for the treatment of the following infections of the eye and its adnexae when caused by susceptible strains of the designated bacteria. Corneal Ulcers: Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus epidermidis. Conjunctivitis: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus (Viridans group), Streptococcus pneumoniae, Haemophilus influenzae. To reduce the development of drug-resistant bacteria and maintain the effectiveness of CILOXAN and other antibac… https://pdf.hres.ca/dpd_pm/00045906.PDF PM date: May 22, 2018 Source product: CILOXAN; DIN 01945270; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Sandoz Ciprofloxacin: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026